IL6 and non-Hodgkin lymphoma: In NHL patients, prophylactic tocilizumab resulted in higher plasma concentrations of IL-6 on days 2 and 6 after CAR-T cell infusion, although the difference compared to patients treated without prophylaxis did not reach statistical significance (Supplementary Fig. 5).